Enanta Pharmaceuticals (ENTA)
(Delayed Data from NSDQ)
$16.00 USD
+1.01 (6.74%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $15.97 -0.03 (-0.19%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum F VGM
Brokerage Reports
Enanta Pharmaceuticals, Inc. [ENTA]
Reports for Purchase
Showing records 101 - 120 ( 164 total )
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
NASH Weekly: 2020 Is Packed With Clinical Data Readouts in NASH
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
As we are three weeks away from JPM Healthcare conference.
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare - Should You Attend AASLD in Boston? Use Our Day-By-Day Calendar to Figure It Out
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare - The Liver Meeting Abstracts Part 2: Our Coverage Universe
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare - September is the Key Month for NASH: Join Our Three Doc Call Series
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
What Does It Take to Lift the Low NASH Sentiment?
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare - Earnings Recap: The More Analysis, The Merrier, Especially When Data-Driven
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
3Q19 - Let''''s Dive Into FXR Biology - Predict EDP-305 NASH Data
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Join Our Three-Part NASH Doc Series on "How Large is the NASH Opportunity?"
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
EDP-938 Did It - Hit the RSV Virus As Hard Is Possible
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y